Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort

Chordia Therapeutics Inc. ( (JP:190A) ) has issued an update.

Chordia Therapeutics Inc. has begun dosing the first patient in the Initial Expansion Cohort of its ongoing Phase 1/2 U.S. clinical trial of rogocekib, following a recommendation from the study’s Safety Review Committee. The transition to the expansion phase, after successful screening at multiple sites, marks a key step in evaluating the cancer drug’s potential across a broader patient group.

The company emphasized that patient safety remains its top priority as it advances the development program and plans to provide updates as the study progresses. This milestone underscores Chordia’s efforts to solidify its position in the oncology space by moving its lead candidate forward while continuing to build out a diversified pipeline of targeted cancer therapies.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen127.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

More about Chordia Therapeutics Inc.

Chordia Therapeutics Inc. is a Japan-based biotechnology company focused on oncology drug discovery and development, with its lead asset rogocekib (CLK inhibitor CTX-712) in a Phase 1/2 clinical study in the U.S. The company is also advancing a pipeline that includes CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors targeting various cancer vulnerabilities.

Average Trading Volume: 1,968,752

Technical Sentiment Signal: Sell

Current Market Cap: Yen8.75B

For an in-depth examination of 190A stock, go to TipRanks’ Overview page.